Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Current Oncology Reports
R Ohno

Abstract

In the pre-imatinib era, treatment outcomes of adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) were dismal. Despite the use of intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), complete remission and overall survival rates were less than 70% and 20%, respectively. However, imatinib, in combination with conventional chemotherapy, has dramatically changed outcomes, producing approximately 95% complete remission and 50% overall survival with or without allogeneic HSCT. Current research is now focusing on how to prevent relapse. Improvement of postremission therapy is indispensable. Although allogeneic HSCT during first complete remission is still the first choice for feasible patients, post-HSCT imatinib therapy and imatinib plus chemotherapy combinations should also be studied. New BCR-ABL tyrosine kinase inhibitors are expected to improve outcomes in imatinib-resistant leukemia. Our hope is that, in the near future, Ph-positive ALL will become a leukemia in which allogeneic HSCT is offered only for relapsed or refractory cases.

References

Mar 22, 2001·Hematology/oncology Clinics of North America·J P Radich
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles LinkerWillis Navarro
Sep 20, 2002·Blood·Hervé DombretUNKNOWN Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group)
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·HaiQing DaiWilliam F Elmquist
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Apr 15, 2003·Bone Marrow Transplantation·I Avivi, A H Goldstone
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Sep 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasDenis Fiere
Dec 1, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paolo AnderliniRichard E Champlin
Apr 2, 2005·British Journal of Haematology·Anindita RoyUNKNOWN Medical Research Council Childhood Leukaemia Working Party
Nov 24, 2005·Hematology·Oliver G Ottmann, Barbara Wassmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.